p16 INK4a/Ki-67 dual stain cytology for cervical cancer screening in Thika district, Kenya

Infectious Agents and Cancer

Miriam Reuschenbach²  Magnus von Knebel Doeberitz²  John Mbithi⁴  Anne Muigai⁵  Peter Wanzala¹  Hamadi Boga⁵  Karanja Wanyoro⁵  Dietmar Schmidt³  Caroline Wangari Ngugi⁶ 

[1] Centre for Public Health Research- Kenya Institute of Medical Research, Nairobi, Kenya;Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, and Clinical Cooperation Unit, German Cancer Research Cancer (DKFZ), Heidelberg, 69120, Germany;Institute of Pathology, Mannheim, A2.2, Germany;Department of Medical Laboratory Sciences, Kenyatta University, Nairobi, Kenya;Faculty of Science, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya;College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

关键词: Ki-67;    p16INK4a;    HPV;    Screening;    Developing countries;    Cervical cancer;   

Others  :  1223385
DOI  :  10.1186/s13027-015-0020-2

 received in 2015-04-09, accepted in 2015-07-09,  发布年份 2015

【 摘 要 】

Background

The identification of suited early detection tests is one among the multiple requirements to reduce cervical cancer incidence in developing countries.

Methods

We evaluated p16 ^INK4a /Ki-67 dual-stain cytology in a screening population in Thika district, Kenya and compared it to high-risk human papillomavirus (HR-HPV) DNA testing and visual inspection by acetic acid (VIA) and Lugol’s iodine (VILI).

Results

Valid results for all tests could be obtained in 477 women. 20.9 % (100/477) were tested positive for HR-HPV DNA, 3.1 % (15/477) had positive VIA/VILI and 8.2 % (39/477) positive p16 ^INK4a /Ki-67 cytology. Of 22 women that showed up for colposcopy and biopsy, 6 women were diagnosed with CIN3 and two with CIN2. All women with CIN2/3 were negative in VIA/VILI screening and positive by HR-HPV DNA testing. But HPV was also positive in 91.7 % (11/12) of women with normal histology. p16 ^INK4a /Ki-67 cytology was positive in all 6 women with CIN3, in one of the two CIN2 and in only 8.3 % (1/12) of women with normal histology.

Conclusions

p16 ^INK4a /Ki-67 cytology is an interesting test for further studies in developing countries, since our findings point to a lower fraction of false positive test results using p16 ^INK4a /Ki-67 cytology compared to HPV DNA testing in a Kenyan screening population. VIA/VILI missed all histology-proven CIN2/3.

【 授权许可】

   
2015 Ngugi et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-917.
• [2]WHO, ICO. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human Papillomavirus and Related Cancers in Kenya. Summary Report 2010. 2010.
• [3]Peto J, Gilham C, Fletcher O, Matthews FE: The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364(9430):249-56.
• [4]de Velde NV, Brisson M, Boily MC: Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007, 165(7):762.
• [5]Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907.
• [6]Soost HJ, Lange HJ, Lehmacher W, Ruffing-Kullmann B: The validation of cervical cytology. Sensitivity, specificity and predictive values. Acta Cytol 1991, 35(1):8-14.
• [7]Benoit AG, Krepart GV, Lotocki RJ: Results of prior cytologic screening in patients with a diagnosis of Stage I carcinoma of the cervix. Am J Obstet Gynecol 1984, 148(5):690-4.
• [8]Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al.: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132(10):810-9.
• [9]WHO. Cervical cancer screening in developing countries: Report of a WHO consultation. 2002.
• [10]Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al.: Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008, 123(1):153-60.
• [11]Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011, 103(5):368-83.
• [12]Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al.: American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012, 137(4):516-42.
• [13]Reuschenbach M, von Knebel DC. Diagnostic tests for the detection of human papillomavirus-associated cervical lesions. Curr Pharm Des in press. 2013;19(8):1358–70.
• [14]McLaughlin-Drubin ME, Crum CP, Munger K: Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci U S A 2011, 108(5):2130-5.
• [15]Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, et al.: The clinical impact of using p16 immunochemistry in cervical histopathology and cytology: An update of recent developments. Int J Cancer 2015, 136(12):2741-51.
• [16]Reuschenbach M, Seiz M, von Knebel DC, Vinokurova S, Duwe A, Ridder R, et al.: Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer 2012, 130(2):388-94.
• [17]Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al.: Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013, 105(20):1550-7.
• [18]Ngugi CW, Schmidt D, Wanyoro RK, Boga H, Wanzala P, Muigai AWT, et al.: Prevalence of human papillomavirus infection by age and cervical cytology in Thika. Kenya. Afr J Health Sci 2011, 19:53-62.
• [19]Gage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, et al.: Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer 2012, 131(12):2903-9.
• [20]von Knebel DM, Reuschenbach M, Schmidt D, Bergeron C: Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012, 9(2):149-63.
• [21]Wentzensen N, Fetterman B, Tokugawa D, Schiffman M, Castle PE, Wood SN, et al.: Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. Cancer Cytopathol 2014, 122(12):914-20.
• [22]Grabe N, Lahrmann B, Pommerencke T, von Knebel DM, Reuschenbach M, Wentzensen N: A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides. Cell Oncol 2010, 32(1–2):109-19.